Zentalis Pharmaceuticals Llc Stock Performance
| ZNTL Stock | USD 3.61 0.02 0.55% |
On a scale of 0 to 100, Zentalis Pharmaceuticals holds a performance score of 4. The firm maintains a market beta of 2.7, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Zentalis Pharmaceuticals will likely underperform. Please check Zentalis Pharmaceuticals' downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to make a quick decision on whether Zentalis Pharmaceuticals' historical returns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Zentalis Pharmaceuticals Llc are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Zentalis Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.55) | Five Day Return 8.41 | Year To Date Return (77.42) | Ten Year Return (84.44) | All Time Return (84.44) |
1 | Insider Trading | 09/12/2024 |
2 | FDA Removes Partial Hold On Zentalis Pharmaceuticals Azenosertib Studies In Patients With Gynecological Cancers | 09/16/2024 |
3 | Biotech Stock Roundup GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates | 09/19/2024 |
4 | We Think Zentalis Pharmaceuticals Needs To Drive Business Growth Carefully | 10/03/2024 |
5 | Disposition of 1603 shares by Vincent Vultaggio of Zentalis Pharmaceuticals at 3.18 subject to Rule 16b-3 | 10/04/2024 |
6 | Acquisition by Roth Iris of 297500 shares of Zentalis Pharmaceuticals at 18.87 subject to Rule 16b-3 | 10/11/2024 |
7 | Undervalued Opportunities US Penny Stocks To Watch In October 2024 | 10/22/2024 |
8 | Vanguard Group Incs Strategic Reduction in Zentalis Pharmaceuticals Inc | 11/05/2024 |
9 | Citadel Advisors LLC Adjusts Stake in Zentalis Pharmaceuticals Inc | 11/15/2024 |
10 | Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm | 11/21/2024 |
| Begin Period Cash Flow | 45.7 M |
Zentalis |
Zentalis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 323.00 in Zentalis Pharmaceuticals Llc on September 2, 2024 and sell it today you would earn a total of 38.00 from holding Zentalis Pharmaceuticals Llc or generate 11.76% return on investment over 90 days. Zentalis Pharmaceuticals Llc is currently generating 0.3351% in daily expected returns and assumes 5.7944% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Zentalis, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zentalis Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zentalis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zentalis Pharmaceuticals Llc, and traders can use it to determine the average amount a Zentalis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0578
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ZNTL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.79 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.34 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Zentalis Pharmaceuticals is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zentalis Pharmaceuticals by adding it to a well-diversified portfolio.
Zentalis Pharmaceuticals Fundamentals Growth
Zentalis Stock prices reflect investors' perceptions of the future prospects and financial health of Zentalis Pharmaceuticals, and Zentalis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zentalis Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (5.16) % | ||||
| Current Valuation | (93.53 M) | ||||
| Shares Outstanding | 71.27 M | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 6.38 X | ||||
| EBITDA | (275.5 M) | ||||
| Net Income | (292.19 M) | ||||
| Cash And Equivalents | 455.22 M | ||||
| Cash Per Share | 7.99 X | ||||
| Total Debt | 43.15 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 9.61 X | ||||
| Book Value Per Share | 4.98 X | ||||
| Cash Flow From Operations | (207.82 M) | ||||
| Earnings Per Share | (2.50) X | ||||
| Market Capitalization | 258.69 M | ||||
| Total Asset | 551.69 M | ||||
| Retained Earnings | (888.56 M) | ||||
| Working Capital | 427.35 M | ||||
About Zentalis Pharmaceuticals Performance
By examining Zentalis Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Zentalis Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Zentalis Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.6 K | -1.7 K | |
| Return On Tangible Assets | (0.53) | (0.56) | |
| Return On Capital Employed | (0.52) | (0.54) | |
| Return On Assets | (0.53) | (0.56) | |
| Return On Equity | (0.67) | (0.70) |
Things to note about Zentalis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Zentalis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zentalis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zentalis Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Zentalis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm |
- Analyzing Zentalis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zentalis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Zentalis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zentalis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zentalis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zentalis Pharmaceuticals' stock. These opinions can provide insight into Zentalis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.50) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.